To diagnose extrahepatic manifestations of NAFLD, clinical practice can take into account suggested screening methods for common comorbidities in NAFLD, such as obtaining fasting blood glucose, hemoglobin A1c, lipid profiles, estimated glomerular filtration rate, urine microalbumin, and the albumin–creatinine ratio. This evidence concerns the gene ALB and metabolic dysfunction-associated steatotic liver disease.